Great Novel Therapeutics Biotech & Medicals (7427.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$59.90 (-0.99%) as of
Key statistics
- Market cap
- 3.17B
- EPS (TTM)
- -2.45
- Dividend yield
- 0.00%
- 52-week range
- 28.45 – 82.80
- Beta
- 0.21
- Revenue (TTM)
- 6.21M
- Profit margin
- 0.00%
- Volume
- 197.71k
About Great Novel Therapeutics Biotech & Medicals
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. It is also developing Kepida to treat HR+/her-2 advanced breast cancer and Peripheral T-cell lymphoma. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was incorporated in 2013 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
- Employees
- 23
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.